Skip to main content

Peer Review reports

From: Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib

Original Submission
19 Feb 2022 Submitted Original manuscript
26 Mar 2022 Reviewed Reviewer Report
6 May 2022 Reviewed Reviewer Report
11 May 2022 Author responded Author comments - Ming Chen
Resubmission - Version 2
11 May 2022 Submitted Manuscript version 2
16 May 2022 Editorially accepted
28 May 2022 Article published 10.1186/s12885-022-09683-1

You can find further information about peer review here.

Back to article page